Levonorgestrel/Etinilestradiol Diario Pensa

Levonorgestrel/Ethinylestradiol, the active ingredient in Levonorgestrel/Etinilestradiol Diario Pensa, is a combined estrogen‑progestogen oral contraceptive presented as a tablet for oral use. It is used to prevent pregnancy in women of reproductive age by inhibiting ovulation, thickening cervical mucus, and altering the endometrium to reduce the chance of implantation.

GNH USA supplies Levonorgestrel/Etinilestradiol Diario Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed under strict quality‑assurance protocols to ensure consistent potency and safety.

Levonorgestrel/Ethinylestradiol is a combined estrogen‑progestogen oral contraceptive used in hormonal contraception.

- Prevention of pregnancy: provides reliable contraceptive protection. - Menstrual cycle regulation: helps establish regular menstrual bleeding patterns. - Acne management: may improve acne associated with hormonal fluctuations.

Levonorgestrel/Ethinylestradiol may be associated with a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort. - Irregular bleeding: spotting or breakthrough bleeding.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Hypertension: significant increase in blood pressure. - Hepatic dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Levonorgestrel/Ethinylestradiol, clinicians should consider several precautionary measures to ensure safe use. - Contraindications: avoid in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or active liver disease. - Smoking: do not prescribe to smokers over 35 years of age due to increased cardiovascular risk. - Medication review: assess concurrent use of enzyme‑inducing drugs that may reduce contraceptive efficacy. - Pregnancy testing: confirm non‑pregnant status before initiating therapy. - Follow‑up: schedule periodic evaluation of blood pressure and menstrual patterns. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and light.

Levonorgestrel/Ethinylestradiol can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Antiepileptics: carbamazepine, phenytoin, phenobarbital may markedly reduce hormone levels, risking contraceptive failure. - Rifampicin: induces hepatic enzymes, decreasing contraceptive efficacy. - St. John’s wort: herbal inducer that can lower plasma concentrations.

Moderate Interactions (Monitor Closely): - Antifungals: ketoconazole, itraconazole may increase hormone levels, potentially enhancing side effects. - Antiretrovirals: protease inhibitors can affect hormone metabolism; monitor for efficacy. - Diuretics: may increase risk of hypertension; observe blood pressure.